Julie S Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12141924/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27â^' Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer. Clinical Cancer Research, 2012, 18, 3281-3292.	7.0	447
2	Novel functions of the CD34 family. Journal of Cell Science, 2008, 121, 3683-3692.	2.0	316
3	The Role of Podocalyxin in Health and Disease. Journal of the American Society of Nephrology: JASN, 2009, 20, 1669-1676.	6.1	179
4	Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer. Clinical Cancer Research, 2014, 20, 1125-1134.	7.0	144
5	Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression. Cancer Research, 2004, 64, 5068-5073.	0.9	136
6	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS ONE, 2016, 11, e0155189.	2.5	112
7	Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood, 2005, 105, 4170-4178.	1.4	103
8	CD34 is a Key Regulator of Hematopoietic Stem Cell Trafficking to Bone Marrow and Mast Cell Progenitor Trafficking in the Periphery. Microcirculation, 2009, 16, 487-496.	1.8	77
9	Tumor-infiltrating B cells and T cells. Oncolmmunology, 2012, 1, 1623-1625.	4.6	77
10	The CD34-Related Molecule Podocalyxin Is a Potent Inducer of Microvillus Formation. PLoS ONE, 2007, 2, e237.	2.5	71
11	Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 ($\hat{1}\pm E/\hat{1}^27$) Tj ETQq1 3	0.78431 1.4	4 rgBT /Overla
12	Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. Breast Cancer Research, 2015, 17, 46.	5.0	58
13	Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. PLoS ONE, 2008, 3, e3409.	2.5	37
14	A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer. Oncolmmunology, 2018, 7, e1371895.	4.6	35
15	The cell surface mucin podocalyxin regulates collective breast tumor budding. Breast Cancer Research, 2016, 18, 11.	5.0	26
16	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clinical Cancer Research, 2016, 22, 2226-2236.	7.0	26
17	Influence of host irradiation on long-term engraftment by CD34-deficient hematopoietic stem cells. Blood, 2007, 110, 1076-1077.	1.4	23
18	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncolmmunology, 2017, 6, e1321184.	4.6	23

JULIE S NIELSEN

#	Article	IF	CITATIONS
19	An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. Journal of Immunological Methods, 2010, 360, 149-156.	1.4	15
20	Avian Models to Study the Transcriptional Control of Hematopoietic Lineage Commitment and to Identify Lineage-Specific Genes. Cells Tissues Organs, 2002, 171, 44-63.	2.3	14
21	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. Journal of Clinical Investigation, 2022, 132, .	8.2	12
22	Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene. Cancer Immunology, Immunotherapy, 2009, 58, 1865-1875.	4.2	9
23	Personalized Immunotherapy Targeting the Cancer Mutanome. , 2016, , 426-433.		1